Cisen Pharmaceutical's sales volume of the winning varieties in the centralized procurement has increased significantly. It is predicted that the sales of the large infusion sector will trend towards stability in the second half of the year. | Live from t

①At the earnings conference, the director of Cisen Pharmaceutical, Xu Xinbing, explained the gross margin and revenue decline of the company in the first half of the year. ②Xu Xinbing said that the company's sales volume of four varieties that were awarded in the eighth batch of centralized procurement showed a significant year-on-year increase. ③Du Zhenxin, the chairman of the company, introduced the company's development of generic drugs and innovative drugs.

cls.cnSep 9 05:55 ET

Decline in revenue from the sales sector, zhejiang shapuaisi pharmaceutical incurs losses in H1 | interpretations

①Affected by factors such as the decline in sales of eye drops and cephalosporin drugs, the H1 performance of Zhejiang Shapuaisi pharmaceutical has declined significantly, resulting in a year-on-year loss. ②The company's main business, the commodity sales sector, saw a year-on-year decrease in revenue of more than 40%.

cls.cnAug 30 09:39 ET

High inventory combined with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined | Interpretations

In the first half of this year, Chongqing Taiji Industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%. The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.

cls.cnAug 22 11:19 ET

Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.

On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.

cls.cnAug 16 10:45 ET

Shanghai Haohai Biological Technology released its semi-annual report: hyaluronic acid product revenue increased by over 50% year-on-year, while revenue from multiple product lines in ophthalmology decreased.

Regarding new products, Shanghai Haohai Biological Technology has successfully obtained approval for the world's first organic cross-linked hyaluronic acid product 'Haimei Yuebai' developed globally in July this year, while the Asia Vets cross-linked collagen product entered the registration and inspection stage in June. Due to the selected price decline in the quantity-based procurement of artificial crystalline lenses, sales revenue decreased year-on-year. As for the consumer market, it is showing signs of fatigue coupled with an increase in the number of competing products, resulting in a decline in revenue from corneal shaping lens business.

cls.cnAug 16 09:23 ET

Hengrui received an FDA warning letter | Jianzhi Research

A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.

wallstreetcnJul 16 23:35 ET